



## (51) International Patent Classification:

*C07D 471/04* (2006.01)    *C07F 9/6561* (2006.01)  
*C07F 9/09* (2006.01)    *A61K 31/675* (2006.01)  
*C07F 9/572* (2006.01)    *A61K 31/496* (2006.01)  
*C07F 9/6524* (2006.01)

## (21) International Application Number:

PCT/US2012/022851

## (22) International Filing Date:

27 January 2012 (27.01.2012)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/437,821    31 January 2011 (31.01.2011)    US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **TRIPP, Jonathan Clive** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **FANFAIR, Dayne Dustan** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **SCHULTZ, Mitchell J.** [US/US]; 2020 Dagmar Place, Decatur, Illinois 62521 (US). **MURUGESAN, Saravanababu** [IN/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **FOX, Richard J.** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick,

New Jersey 08903 (US). **CHEN, Chung-Pin H.** [US/US]; 92 Joshua Trail, Madison, Connecticut 06443 (US). **IVY, Sabrina E.** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **PAYACK, Joseph Francis** [US/US]; c/o Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903 (US). **DOUBLEDAY, Wendel W.** [US/US]; 7806 129th Drive Southeast, Snohomish, Washington 98290 (US).


(74) Agents: **LEVIS, John F.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: METHODS OF MAKING HIV ATTACHMENT INHIBITOR PRODRUG COMPOUND AND INTERMEDIATES



(I)

(57) Abstract: A method for making the compound of Formula (I) is set forth using alkylation, amidation, chlorination and phosphate installation procedures.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

— *as to the applicant's entitlement to claim the priority of  
the earlier application (Rule 4.17(iii))*

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii))*

**Published:**

— *with international search report (Art. 21(3))*